These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 21596235)

  • 21. Adriamycin cardiomyopathy: pathophysiology and prevention.
    Singal PK; Iliskovic N; Li T; Kumar D
    FASEB J; 1997 Oct; 11(12):931-6. PubMed ID: 9337145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Doxorubicin-induced cardiomyopathy.
    Ginsburg AD
    N Engl J Med; 1999 Feb; 340(8):654; author reply 655. PubMed ID: 10049086
    [No Abstract]   [Full Text] [Related]  

  • 23. Troponins for predicting cardiotoxicity from cancer therapy.
    Sparano JA; Wolff AC; Brown D
    Lancet; 2000 Dec; 356(9246):1947-8. PubMed ID: 11130520
    [No Abstract]   [Full Text] [Related]  

  • 24. Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model.
    Xiang P; Deng HY; Li K; Huang GY; Chen Y; Tu L; Ng PC; Pong NH; Zhao H; Zhang L; Sung RY
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):343-9. PubMed ID: 18379782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression.
    Neilan TG; Jassal DS; Scully MF; Chen G; Deflandre C; McAllister H; Kay E; Austin SC; Halpern EF; Harmey JH; Fitzgerald DJ
    Eur Heart J; 2006 May; 27(10):1251-6. PubMed ID: 16624831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Drug-induced myocarditis and cardiomyopathy].
    Takemoto Y; Yoshiyama M
    Nihon Rinsho; 2012 Aug; 70 Suppl 6():589-92. PubMed ID: 23156578
    [No Abstract]   [Full Text] [Related]  

  • 27. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.
    Hequet O; Le QH; Moullet I; Pauli E; Salles G; Espinouse D; Dumontet C; Thieblemont C; Arnaud P; Antal D; Bouafia F; Coiffier B
    J Clin Oncol; 2004 May; 22(10):1864-71. PubMed ID: 15143078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. S-diclofenac protects against doxorubicin-induced cardiomyopathy in mice via ameliorating cardiac gap junction remodeling.
    Zhang H; Zhang A; Guo C; Shi C; Zhang Y; Liu Q; Sparatore A; Wang C
    PLoS One; 2011; 6(10):e26441. PubMed ID: 22039489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adriamycin-induced myocardial toxicity: new solutions for an old problem?
    Outomuro D; Grana DR; Azzato F; Milei J
    Int J Cardiol; 2007 Apr; 117(1):6-15. PubMed ID: 16863672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity.
    Cole MP; Chaiswing L; Oberley TD; Edelmann SE; Piascik MT; Lin SM; Kiningham KK; St Clair DK
    Cardiovasc Res; 2006 Jan; 69(1):186-97. PubMed ID: 16157314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correspondence re: O. J. Arola et al., acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res., 60: 1789-1792, 2000.
    Auner HW; Tinchon C; Linkesch W; Halwachs-Baumann G; Sill H
    Cancer Res; 2001 Mar; 61(5):2335-6. PubMed ID: 11280807
    [No Abstract]   [Full Text] [Related]  

  • 32. Hyperbaric oxygen therapy does not potentiate doxorubicin-induced cardiotoxicity in rats.
    Karagoz B; Suleymanoglu S; Uzun G; Bilgi O; Aydinoz S; Haholu A; Turken O; Onem Y; Kandemir EG
    Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):287-92. PubMed ID: 18248515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
    Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
    Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epo 'cytokine-doping' of heart disease patients, will it work?
    Jørgensen E; Bindslev L; Ripa RS; Kastrup J
    Eur Heart J; 2006 Aug; 27(15):1767-8. PubMed ID: 16818456
    [No Abstract]   [Full Text] [Related]  

  • 35. Doxorubicin cardiomyopathy.
    Chatterjee K; Zhang J; Honbo N; Karliner JS
    Cardiology; 2010; 115(2):155-62. PubMed ID: 20016174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular late effects.
    Camp-Sorrell D
    Oncology (Williston Park); 2008 Feb; 22(2 Suppl Nurse Ed):42-4. PubMed ID: 18431900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The effect of erythropoetin on doxorubicin-induced oxidative stress in rat kidney].
    Saenko IuV; Shutov AM; Napalkova SM; Selivanova OS; Evstegneeva EIu
    Eksp Klin Farmakol; 2005; 68(6):52-4. PubMed ID: 16405037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigation of doxorubicin tissue toxicity: does amifostine provide chemoprotection? An experimental study.
    Rigatos SK; Stathopoulos GP; Dontas I; Perrea-Kotsarelis D; Couris E; Karayannacos PE; Deliconstantinos G
    Anticancer Res; 2002; 22(1A):129-34. PubMed ID: 12017274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy.
    Li L; Takemura G; Li Y; Miyata S; Esaki M; Okada H; Kanamori H; Khai NC; Maruyama R; Ogino A; Minatoguchi S; Fujiwara T; Fujiwara H
    Circulation; 2006 Jan; 113(4):535-43. PubMed ID: 16449733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The cardiotoxicity of anticancer agents].
    Wakasugi S
    Ryoikibetsu Shokogun Shirizu; 1996; (14):83-7. PubMed ID: 9047803
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.